John Hanna appointed GM , endocrinology, breast cancer and lymphoma; Morten Frost to join company as GM , pulmonology SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 17, 2020-- Veracyte (Nasdaq: VCYT) today announced a new general manager-based structure to advance the company’s growing roster
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 5, 2020-- Veracyte, Inc. (Nasdaq: VCYT), a pioneering genomic diagnostics company, announced that the Federal Joint Committee (G-BA) has approved its Prosigna® Breast Cancer Gene Signature Assay. The G-BA decision to reimburse the Prosigna test
Revenue of $31.1 Million ; Product and Testing Revenue Increased 79% Over Second Quarter of 2020 Achieved Key Reimbursement Milestones Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 2, 2020-- Veracyte, Inc .
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 30, 2020-- Veracyte, Inc ., (Nasdaq: VCYT) announced today that findings from the first study evaluating the molecular drivers underlying multiple prognostic genomic breast cancer tests were published in the Journal of Clinical Oncology (JCO).
RNA sequencing and novel machine learning algorithms generate a test that improves lung cancer diagnosis using brushings from the main lung airway SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 22, 2020-- Veracyte, Inc . (Nasdaq: VCYT) today announced the publication of a manuscript detailing
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 19, 2020-- Veracyte, Inc ., (Nasdaq: VCYT) today announced that new data presented at the CHEST Annual Meeting 2020 show that a genomic smoking index developed for use on samples obtained from the main lung airway can also be detected in nasal
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 14, 2020-- Veracyte, Inc. (Nasdaq: VCYT) announced today that an oral presentation will be given at the CHEST Annual Meeting 2020 reinforcing the foundational technology behind its noninvasive nasal swab test to identify lung cancer risk in
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 7, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that it will release its financial results for the third quarter of 2020 after the close of market on Monday, November 2, 2020 . Company management will host a conference call and webcast to
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 24, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that the Centers for Medicare and Medicaid Services (CMS) has approved new Advanced Diagnostic Laboratory Test (ADLT) status for the Envisia ® Genomic Classifier.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 15, 2020-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to participate in two virtual investor conferences this week: 2020 Cantor
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
